Gathering the record
Relay is organizing the evidence and source boundaries.
Zinc-dependent thymic nonapeptide hormone
Thymulin is a zinc-bound nine-amino-acid hormone made by thymic epithelial cells. Human studies mostly measure the body's own thymulin activity and how it changes with zinc status, age, thyroid function, diabetes, or illness. Relay found no established human treatment program showing that administered synthetic Thymulin improves immune function, inflammation, longevity, or disease outcomes.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
Thymulin is a nine-amino-acid hormone made by cells in the thymus and activated by zinc. It participates in the connection between immune, nutritional, and hormone systems.
Researchers measure the body's own thymulin activity to understand how thymic function changes with age, zinc status, thyroid disease, diabetes, kidney disease, and other health conditions.
Human studies consistently show that measured endogenous thymulin activity changes with zinc and endocrine state. In some studies, correcting zinc deficiency or an underlying thyroid condition restored the measured activity. Those interventions did not administer synthetic thymulin.
Relay found no established human treatment program showing that administered synthetic zinc-bound thymulin improves immunity, inflammation, disease outcomes, or longevity. Product identity, human exposure, pharmacokinetics, safety, and clinical benefit therefore remain unestablished.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
Published human research mainly measured naturally produced thymulin before and after changes in zinc or underlying disease. It did not establish a synthetic-thymulin treatment program.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Human biomarker and zinc-intervention studies characterize endogenous thymulin; synthetic administration evidence is absent.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
The endogenous relationship is reproducible, but therapeutic effects of synthetic thymulin remain untested.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Zinc supplementation and treatment of thyroid disease cannot be reframed as thymulin administration. The section remains incomplete because product identity, exposure, safety, and clinical-outcome evidence are not established. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
Human studies consistently demonstrate zinc-dependent endogenous thymulin activity and modulation by zinc and endocrine state; they do not establish administered synthetic-Thymulin efficacy.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Whether administered synthetic zinc-bound Thymulin has a reproducible pharmacologic identity, target exposure, pharmacokinetics, human safety profile, or clinical benefit without disrupting complex thymic and immune-endocrine regulation.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
The zinc-free peptide is often called serum thymic factor or FTS, while the zinc-bound active complex is called thymulin.
Human studies commonly ask how age, zinc, endocrine disease, or illness changes the body's own thymic-hormone activity.
In these studies, zinc was the intervention and endogenous thymulin was an outcome or biomarker.
This supports a biological role for the endogenous hormone, not a proven broad immune-boosting treatment.
Direct evidence for immune benefit, inflammation reduction, longevity, analgesia, endocrine effects, or disease treatment remains unestablished.
Association with immune physiology does not establish that more hormone is better or that systemic administration is safe.
Synthetic peptide, zinc-free FTS, zinc-bound thymulin, analog constructs, and gene-delivery systems are not interchangeable.
Mechanisms
Thymulin is the biologically active zinc complex of the nonapeptide historically called serum thymic factor. Zinc binding produces a conformational and assay-active state associated with thymic epithelial secretion and T-cell differentiation biology. Human studies describe endogenous activity across zinc deficiency, endocrine disease, diabetes, renal disease, and other conditions; selected zinc-repletion studies increased endogenous measured activity. Laboratory research supports immune-endocrine signaling, while therapeutic concepts such as anti-inflammatory, analgesic, endocrine, and gene-delivered analog effects remain predominantly preclinical. Endogenous levels, zinc supplementation, synthetic peptide, zinc-free FTS, zinc-bound thymulin, analogs, and gene-delivery constructs must remain separate evidence records.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Cell-culture study of zinc uptake, thymulin secretion, and lymphocyte responses
Human thymic epithelial cells and peripheral lymphocytes
Interleukin-1 and zinc influenced thymulin-related secretion and downstream lymphocyte laboratory responses.
Study administration: Interleukin-1, zinc, and cell-culture conditions
Limitations: Cell-culture immune signaling does not establish systemic clinical benefit, immune protection, or safety from administered Thymulin.
Cross-sectional plasma and zinc-saturation analysis
15 young people with type 1 diabetes and age-matched controls
Active zinc-bound thymulin was reduced while inactive zinc-saturable hormone was elevated; adding zinc in vitro restored measured activity.
Study administration: In-vitro zinc addition to plasma; no Thymulin administration
Limitations: An endogenous biomarker finding does not establish that synthetic Thymulin treats diabetes or immune dysfunction.
Human oral zinc supplementation study
People with chronic renal failure
Zinc supplementation increased measured total and zinc-bound endogenous thymulin activity.
Study administration: Oral zinc supplementation; no synthetic Thymulin administration
Limitations: This supports zinc-dependent endogenous physiology and cannot be reframed as evidence for a Thymulin peptide product.
Diet-induced and clinical zinc-deficiency models before and after zinc repletion
Healthy volunteers and mildly zinc-deficient adults with and without sickle-cell disease
Mild zinc deficiency reduced endogenous serum thymulin activity and selected immune measures, which improved after zinc repletion.
Study administration: Dietary zinc depletion or zinc supplementation; no synthetic Thymulin treatment
Limitations: The intervention was zinc correction. It does not establish an indication, dose, route, or safety profile for administered Thymulin.
Cross-sectional measurement before and after treatment of thyroid dysfunction
People with hyperthyroidism or hypothyroidism and healthy controls
Circulating thymulin activity was higher in hyperthyroidism and lower in hypothyroidism, with changes reversing after treatment of thyroid status.
Study administration: Treatment of the underlying thyroid condition; no Thymulin administration
Limitations: This demonstrates endocrine regulation of endogenous thymic activity, not therapeutic benefit from administered synthetic Thymulin.
PubMed and ClinicalTrials.gov searches
Population not stated.
Relay did not identify an established administered synthetic-Thymulin human treatment program with clinical outcomes.
Study administration: Not stated in the current record.
Limitations: Search audits cannot prove that no unpublished or nonregistered exposure exists, but they prevent endogenous-hormone measurements from being presented as treatment trials.
Safety snapshot
No source-qualified adverse-event pattern is represented in the current record.
Evidence boundaryHuman exposure is present, but the record is not detailed enough to characterize a reliable adverse-event pattern.
The current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryNot FDA approved; no established administered synthetic-Thymulin human treatment program or product standard identified Whether administered synthetic zinc-bound Thymulin has a reproducible pharmacologic identity, target exposure, pharmacokinetics, human safety profile, or clinical benefit without disrupting complex thymic and immune-endocrine regulation.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-07-31
2026-07-31
2014-01-01 · PMID 24588820 · DOI 10.2174/1381612820666140130211157
1992-01-01 · PMID 1502195
1989-07-01 · PMID 2737365 · DOI 10.2337/diab.38.7.932
1989-01-01 · PMID 2909550
1989-01-01 · PMID 2657247 · DOI 10.1007/BF02985220
1988-01-01
1986-03-01 · PMID 3944232 · DOI 10.1210/jcem-62-3-474
1984-02-14 · PMID 6538097 · DOI 10.1016/0304-4165(84)90116-8
1982-01-01 · PMID 6957870
No direct primary administration source was verified for this exact identity. The limitation is the finding.